SK Biopharm's Cenobamate Receives New Drug Approval in Japan
Approved Through Ono Pharmaceutical
SK Biopharm announced on September 16 that its partner, Ono Pharmaceutical, has received new drug approval from the Japanese Ministry of Health, Labour and Welfare for the antiepileptic drug Cenobamate (Japanese brand name Exkiscopri).
Japan is the world's second-largest epilepsy market by individual country, following the United States. It is estimated that there are approximately one million patients. With this approval, Cenobamate has established a foothold for entering the Japanese market, which has a high level of unmet medical needs.
This approval is based on the results of a multinational Phase 3 clinical trial (YKP3089C035), which targeted adult patients with partial-onset epilepsy in Korea, China, and Japan. Cenobamate adjunctive therapy demonstrated a significant reduction in seizure frequency compared to placebo, meeting the primary endpoint.
SK Biopharm signed a licensing and commercialization agreement with Ono Pharmaceutical for Cenobamate in Japan in October 2020. Under this approval, the company will receive a contractual milestone payment and, in the future, royalties based on Japanese sales.
Cenobamate has received approval in more than 45 countries and regions worldwide, including the United States and Europe. In the United States, SK Biopharm's local subsidiary SK Life Science distributes the drug directly, while commercialization in other major markets is conducted through regional partnerships. In Japan, additional Phase 3 clinical trials are underway in adolescent and adult patients with primary generalized tonic-clonic seizures (PGTC) and pediatric patients with partial-onset seizures.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Dong-hoon, CEO of SK Biopharm, stated, "With this approval, we have completed the foundation for entering the major Northeast Asian markets of Korea, China, and Japan. We will now focus on achieving commercialization results that lead to actual patient prescriptions in these markets."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.